Form 4: Opaleye Management Increases Stake in Codexis, Acquiring 100,000 Shares

Opaleye Management Inc., a 10% owner and director of Codexis, Inc., acquired 100,000 shares of common stock at $2.82 per share, increasing its indirect beneficial ownership.

Summary

• Opaleye Management Inc., a 10% owner and director of Codexis, Inc. (CDXS), acquired 100,000 shares of the company's common stock.
• The transaction occurred on July 18, 2025, with shares purchased at a price of $2.82 per share.
• Following this acquisition, Opaleye, L.P. indirectly beneficially owns 12,450,000 shares of Codexis common stock.
• An additional 250,000 shares are indirectly beneficially owned by a separately managed account managed by Opaleye Management Inc.
• Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.

Sentiment

Score: 8

Explanation: The acquisition of additional shares by a significant insider (10% owner and director) indicates strong confidence in the company's prospects and valuation, which is generally a very positive signal for investors.

Positives

• A significant insider, Opaleye Management Inc., which is a 10% owner and director, increased its stake in Codexis, Inc., signaling confidence in the company's future prospects.
• The acquisition of 100,000 shares at $2.82 per share demonstrates a direct investment at a specific valuation, potentially indicating a belief that the stock is undervalued at this price point.

Negatives

• No negative information was disclosed in this Form 4 filing, which reports an acquisition of shares.

Risks

• No specific risks were detailed in this Form 4 filing, which primarily reports changes in beneficial ownership.

Future Outlook

This Form 4 filing, a statement of changes in beneficial ownership, does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.
• The filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

In the biotechnology sector, insider buying by significant shareholders or directors can often be interpreted as a sign of confidence in the company's pipeline, strategic direction, or undervaluation, especially given the capital-intensive nature and long development cycles typical of the industry. This acquisition by Opaleye Management Inc. suggests a positive internal view of Codexis's prospects.

Comparison to Industry Standards

• This Form 4 filing, which reports an insider stock acquisition, does not provide information suitable for direct comparison to industry-wide financial or operational benchmarks, nor does it mention specific comparable companies or projects.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters were reported in this Form 4 filing.

Related Party Transactions

• The acquisition of 100,000 shares by Opaleye Management Inc., a 10% owner and director of Codexis, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the increased stake by a significant owner and director as a positive indicator of confidence in the company's future performance and valuation, potentially leading to increased investor interest.

Next Steps

• No specific future actions, events, or milestones were mentioned in this Form 4 filing, which is solely a report of changes in beneficial ownership.

Key Dates

Recommendation

The acquisition of shares by a 10% owner and director, Opaleye Management Inc., signals strong insider confidence in Codexis, Inc.'s current valuation and future prospects. This insider buying activity suggests that the reporting person believes the stock is undervalued or poised for growth, making it a potentially attractive entry point for investors.

Keywords

Codexis, CDXS, Opaleye Management, Insider Trading, Stock Acquisition, Beneficial Ownership, Biotechnology, Enzyme Engineering, SEC Form 4